id	author	title	date	pages	extension	mime	words	sentence	flesch	summary	cache	txt
dpc-4967	Pasek, Marek; Sticová, Eva; Marques, Emanuel; Tretera, Vojtěch; Arenberger, Petr; Arenbergerová, Monika	Lichen Planus-Like Exanthema Induced by Anti-PD-1 and Anti-LAG-3 Combination Immunotherapy Could Potentially Predict the Treatment Response in Metastatic Melanoma	2025	3	.pdf	application/pdf	924	74	55	2025;15(1):4967 1 Lichen Planus-Like Exanthema Induced by Anti-PD-1 and Anti-LAG-3 Combination Immunotherapy Could Potentially Predict the Treatment Response in Metastatic Melanoma Marek Pásek1, Eva Sticová2, Emanuel Marques3,4, Vojtěch Tretera1, Petr Arenberger1, Monika Arenbergerová1 1 Department of Dermatology and Venereology, Third Faculty of Medicine, Charles University and Královské Vinohrady University Hospital, Prague, Czech Republic 2 Department of Pathology, Third Faculty of Medicine, Charles University, and Královské Vinohrady University Hospital, Prague, Czech Republic 3 Department of Dermatology and Venereology, St. Joseph Local Health Unit, Lisbon, Portugal 4 Department of Dermatology and Venereology, NOVA Medical School, University Lisbon, Portugal Key words: Melanoma, Anti-PD-1, Anti-LAG-3, Adverse Events Citation: Pásek M, Sticová E, Marques E, Tretera V, Arenberger P, Arenbergerová M. Lichen Planus-Like Exanthema Induced by Anti-PD-1 and Anti-LAG-3 Combination Immunotherapy Could Potentially Predict the Treatment Response in Metastatic Melanoma. E-mail: marek.pasek@seznam.cz Introduction A combination therapy using nivolumab (anti-PD-1) and relatlimab (anti-LAG-3) has been compared head-to-head with a monotherapy of nivolumab and shown a statistically significant improvement in progression-free survival rate, with minimal increase in toxicity	cache/dpc-4967.pdf	txt/dpc-4967.txt